Janssen to Address NICE's Concerns Following Another English Funding No For Spravato
UK health technology assessment body NICE says the cost-effectiveness estimates for the nasal spray for treating hard-to-treat depression are much higher than what it considers to be cost-effective.
You may also be interested in...
Discrepancy in access to Janssen’s antidepressant nasal spray between patients in Scotland and those in England and the rest of the UK may be due to the differences in methodologies and approaches used by the health technology assessment bodies.
The latest US FDA approvals and actions from the Pink Sheet’s US FDA Performance Tracker.
The US FDA approved the esketamine nasal spray for adults with major depressive disorder with suicidal ideation or behavior, following its initial approval in 2019 for treatment-resistant depression.